Search

everythinglearnresearchcommunity

for

Search:↓

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Photodynamic therapy improved skin issues from sorafenib when other treatments failed.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Ruxolitinib treatment may cause eyelash growth.

Merremia peltata leaf extract, particularly the bufotalinin compound, shows potential for treating hair loss.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Gefitinib can cause rare scarring hair loss.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

The FDA approved a new Pfizer drug for hair loss in teens.

A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Sonidegib effectively treated advanced basal cell carcinoma with mild side effects.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Erlotinib can cause unexpected side effects like eyelash growth and scarring.

Upadacitinib improved multiple immune-related conditions in one patient.

The treatment was ineffective in humans.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Semecarpus anacardium leaf extracts may offer safe, effective cancer treatment alternatives.

Ruxolitinib cream may help treat severe hair loss in children.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

A man developed alopecia areata after starting cancer treatment with vandetanib.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.